Literature DB >> 30990686

New Electrophiles and Strategies for Mechanism-Based and Targeted Covalent Inhibitor Design.

Sneha Ray1, Andrew S Murkin1.   

Abstract

Covalent inhibitors are experiencing a growing resurgence in drug design and are an increasingly useful tool in molecular biology. The ability to attach inhibitors to their targets by a covalent linkage offers pharmacodynamic and pharmacokinetic advantages, but this can also be a liability if undesired off-target reactions are not mitigated. The discovery of new electrophilic groups that react selectively with specific amino acid residues is therefore highly desirable in the design of targeted covalent inhibitors (TCIs). Additionally, the ability to control the reactivity through exploitation of the target enzyme's machinery, as in mechanism-based inhibitors (MBIs), greatly benefits from the discovery of new strategies. This Perspective showcases recent advances in electrophile development and their application in TCIs and MBIs, exhibiting high selectivity for their targets.

Year:  2019        PMID: 30990686     DOI: 10.1021/acs.biochem.9b00293

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  13 in total

1.  Small-molecule covalent bond formation at tyrosine creates a binding site and inhibits activation of Ral GTPases.

Authors:  Khuchtumur Bum-Erdene; Degang Liu; Giovanni Gonzalez-Gutierrez; Mona K Ghozayel; David Xu; Samy O Meroueh
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-16       Impact factor: 11.205

Review 2.  Inverse Drug Discovery identifies weak electrophiles affording protein conjugates.

Authors:  Gabriel M Kline; Karina Nugroho; Jeffery W Kelly
Journal:  Curr Opin Chem Biol       Date:  2022-01-20       Impact factor: 8.822

3.  Detection of an enzyme isomechanism by means of the kinetics of covalent inhibition.

Authors:  S A Adediran; Michael J Morrison; R F Pratt
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2021-06-02       Impact factor: 4.125

4.  Docking-generated multiple ligand poses for bootstrapping bioactivity classifying Machine Learning: Repurposing covalent inhibitors for COVID-19-related TMPRSS2 as case study.

Authors:  Ma'mon M Hatmal; Omar Abuyaman; Mutasem Taha
Journal:  Comput Struct Biotechnol J       Date:  2021-08-19       Impact factor: 7.271

5.  Discovery and Characterization of a Cryptic Secondary Binding Site in the Molecular Chaperone HSP70.

Authors:  Suzanne O'Connor; Yann-Vaï Le Bihan; Isaac M Westwood; Manjuan Liu; Oi Wei Mak; Gabriel Zazeri; Ana P R Povinelli; Alan M Jones; Rob van Montfort; Jóhannes Reynisson; Ian Collins
Journal:  Molecules       Date:  2022-01-26       Impact factor: 4.411

6.  A targeted covalent inhibitor of p97 with proteome-wide selectivity.

Authors:  Zi Ye; Ke Wang; Lianguo Chen; Xiaofeng Jin; Hao Chen; Guanghui Tang; Shao Q Yao; Zhiqiang Feng; Chong-Jing Zhang
Journal:  Acta Pharm Sin B       Date:  2021-09-08       Impact factor: 11.413

Review 7.  Advances in UDP-N-Acetylglucosamine Enolpyruvyl Transferase (MurA) Covalent Inhibition.

Authors:  Maycon Vinicius Damasceno de Oliveira; Renan Machado Furtado; Kauê S da Costa; Serhii Vakal; Anderson H Lima
Journal:  Front Mol Biosci       Date:  2022-07-20

8.  Steroidal Antimetabolites Protect Mice against Trypanosoma brucei.

Authors:  Minu Chaudhuri; Ujjal K Singha; Boden H Vanderloop; Anuj Tripathi; W David Nes
Journal:  Molecules       Date:  2022-06-25       Impact factor: 4.927

Review 9.  PROTAC targeted protein degraders: the past is prologue.

Authors:  Miklós Békés; David R Langley; Craig M Crews
Journal:  Nat Rev Drug Discov       Date:  2022-01-18       Impact factor: 112.288

10.  An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor.

Authors:  Daniel Zaidman; Paul Gehrtz; Mihajlo Filep; Daren Fearon; Ronen Gabizon; Alice Douangamath; Jaime Prilusky; Shirly Duberstein; Galit Cohen; C David Owen; Efrat Resnick; Claire Strain-Damerell; Petra Lukacik; Haim Barr; Martin A Walsh; Frank von Delft; Nir London
Journal:  Cell Chem Biol       Date:  2021-06-25       Impact factor: 8.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.